MYLAN-ATOMOXETINE CAPSULE
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
12-01-2016
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE)
Inapatikana kutoka:
MYLAN PHARMACEUTICALS ULC
ATC kanuni:
N06BA09
INN (Jina la Kimataifa):
ATOMOXETINE
Kipimo:
60MG
Dawa fomu:
CAPSULE
Tungo:
ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) 60MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
30/100
Dawa ya aina:
Prescription
Eneo la matibabu:
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0150434005; AHFS:
Idhini hali ya:
CANCELLED POST MARKET
Idhini ya tarehe:
2018-07-12
Tabia za bidhaa
MYLAN-ATOMOXETINE Product Monograph
Page 1
PRODUCT MONOGRAPH
PR
MYLAN-ATOMOXETINE
(ATOMOXETINE CAPSULES, USP)
18 MG, 25 MG, 40 MG, 60 MG, 80 MG AND 100 MG ATOMOXETINE (AS
ATOMOXETINE HYDROCHLORIDE)
SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR
FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
MYLAN PHARMACEUTICALS ULC
Date of Revision:
85 Advance Rd.
January 7, 2016
Etobicoke, On, M8Z 2S6
Canada
SUBMISSION CONTROL NO: 190331
MYLAN-ATOMOXETINE Product Monograph
Page 2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
SPECIAL DIAGNOSTIC CONSIDERATIONS
.......................................................................
3
NEED FOR COMPREHENSIVE TREATMENT PROGRAM
............................................... 4
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
..........................................................................................................
12
DRUG ABUSE AND DEPENDENCE
.....................................................................................
21
DRUG INTERACTIONS
...........................................................................................................
22
DOSAGE AND ADMINISTRATION
.....................................................................................
24
OVERDOSAGE
..........................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 28
STORAGE AND STABILITY
........................................
Soma hati kamili
